Mepolizumab for mucus-related COPD in former smokers
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests if the drug mepolizumab can reduce mucus blockages in the airways of people with COPD and frequent flare-ups. It may help improve breathing and reduce flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old.
- You have COPD with frequent flare-ups (at least 2 moderate or 1 severe in the past year).
- You have elevated eosinophils (a type of white blood cell) in your blood, as shown by a blood test.
- You have mucus blockages seen on a CT scan of your chest.
- You are a former smoker (quit at least a year ago) with a smoking history of at least 10 pack-years.
- You are currently taking a combination of inhaled steroids, LAMA, and LABA (commonly called triple therapy) for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
This trial tests how well mepolizumab works for people with asthma or a related condition called EGPA, and looks for markers in the blood that may predict organ damage or treatment response.
This study looks at blood and other measures (biomarkers) to understand how well mepolizumab helps people with nasal polyps, with or without asthma. It aims to find response clues that could help personalize treatment in the future.
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.